Journal List > Clin Nutr Res > v.9(1) > 1141605

Pasdar, Oubari, Zarif, Abbasi, Pourmahmoudi, and Hosseinikia: Effects of Quercetin Supplementation on Hematological Parameters in Non-Alcoholic Fatty Liver Disease: a Randomized, Double-Blind, Placebo-Controlled Pilot Study

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease which has become a public health concern. Since oxidative stress plays a crucial role in the pathogenesis of NAFLD, subsequent hematological disorders are expected. Therefore, antioxidant compounds such as quercetin could ameliorate the related side-effect of oxidative stress. The aim of the current study was to assess the effect of quercetin on hematological parameters in NAFLD patients. A randomized, double-blind, placebo-controlled trial was conducted as a pilot study. In this study 90 patients with NAFLD were supplemented with either a quercetin or a placebo capsule twice daily (500 mg) for 12 weeks. Blood sample was obtained for laboratory parameters at baseline and the end of week 12. End of trial values for red blood cell (RBC; p = 0.002), mean corpuscular hemoglobin concentration (p = 0.029), and mean platelet volume (p = 0.017), significantly increased and the levels of mean corpuscular volume (MCV; p = 0.023), RBC distribution width-coefficient of variation (p = 0.005), platelet distribution width (p = 0.015), and ferritin (p = 0.002) significantly decreased compared to the baseline in group receiving quercetin. Between group analysis revealed that RBC significantly increased (p = 0.025) but, mean corpuscular volume (p = 0.004), mean corpuscular hemoglobin (MCH; p = 0.002), and ferritin (p = 0.013) significantly decreased compared to placebo group. In this work quercetin showed significant effect on RBC, ferritin, MCV, and MCH in intervention group.

Trial Registration

Iranian Center for Clinical Trials Identifier: IRCT2016060628299N1

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD), which has attracted much attention in recent years, is a chronic liver disease and is known as the major cause of liver enzymes disorder in recent decades. The disease is characterized by an increase in fat accumulation by about 5%–10% of the liver's weight in patients without a history of significant consumption of alcohol [1], steatogenic medication or hereditary disorders [2]. This clinicopathological condition is related to a spectrum of liver disorders ranging from steatosis, steatohepatitis and cirrhosis which can be developed to hepatocellular carcinoma over time. Symptoms of nonalcoholic steatohepatitis are presented in 5%–10% of NAFLD cases, and 1.3% of them are developed to cirrhosis [3]. Risk factors of NAFLD include central obesity, type 2 diabetes, dyslipidemia, high blood pressure, sedentary life-style and unhealthy dietary pattern [4]. The prevalence rate of NAFLD is about 33.9% in the general population of Iran [5]. From the precautionary medical point of view, the early diagnosis of this disease can prevent subsequent liver dysfunctions through screening and following appropriate interventions [67].
Quercetin (3-3-4-5-7 pentahydroxy flavones, C15H10O7) [8], contains 5 hydroxyl groups and numbers of derivatives including galactoside, glucoside, xylose, rhamnose, and glucuronide [9]. It is a polyphenolic compound, which is widely distributed in edible vegetables such as caper, onion, tea, and apple [8]. Quercetin absorption is mainly mediated using the sodium-glucose transporter or lactase phlorizin hydrolase in the enterocytes (mostly in the upper part of the small intestine) [10].
It is almost totally confirmed that oxidative stress plays a crucial role in the pathogenesis of NAFLD [11]. Studies have demonstrated that red blood cell (RBC) destruction and death are mainly mediated by oxidative stress. The continuous exposure to reactive oxygen species (ROS) might cause RBC membrane to be fragile and make them susceptible to damage [1213]. This oxidative damage is largely caused by the reaction of ROS with membrane lipids and proteins, which can affect membrane structure and function. One of the involved possible mechanisms is that oxidative stress has shown to inhibit Ca-ATPase, which can result in elevation of intracellular calcium concentration and subsequent leakage of potassium from the RBC and finally shrinkage of the cell and impaired deformability [14]. Previous studies have also indicated that one-third of NAFLD patients are iron deficient, and red blood cell distribution width (RDW) is significantly increased in NAFLD cases mainly because of inflammatory conditions of this disease [1516]. We hypothesized that quercetin as a potent antioxidant, could protect RBC membrane against oxidative damage, and improve the hematological parameters [171819]. To the best of our knowledge, this is the first study, which evaluates the effect of quercetin supplementation on hematological parameters in NAFLD patients, in the form of a placebo-controlled trial.

MATERIALS AND METHODS

Recruitment and selection of subjects

This work was conducted on 90 men and women, with the ages of between 18–65 years old with NAFLD as approved by ultrasonography recruited from radiology clinic of Imam Khomeini hospital in Kermanshah, Kermanshah province, Iran. From a total of 120 interviewed patients, 90 of them were qualified based on inclusion criteria including: Body mass index between 25–40 kg/m2, no history of alcohol abuse, lack of acute and chronic disease such as liver disorders (hepatitis B and C), Wilson's disease, cirrhosis, autoimmune disease, and thyroid disorders plus no previous exposure to pesticides and insecticides and not taking steatogenic medications, which potentially interact with quercetin (anticoagulant agents, inhibitors of CYP3A4, etc.). We also selected subjects who were not pregnant and lactating, and also had no either weight loss surgery in the recent year, neither a moderate nor severe weight loss within three months before sampling. Exclusion criteria were as follows: unwilling to continue cooperation, developing diseases that require special treatment and being pregnant during follow up, migration and not consuming more than 10% of supplements in each follow-up period.

Study design and randomization

All eligible patients with NAFLD were enrolled in this study in November 2017. The study protocol was approved by the Ethics Committee of the School of Public Health (KUMS.REC.1395.79) in Kermanshah University of Medical Sciences and was with respect to the declaration of Helsinki of the world medical association. This study was also registered in the Iranian Center for Clinical Trials (IRCT2016060628299N1). The patients signed an informed consent form after a full review of the inclusion and exclusion criteria and explaining the risks and benefits of the study. From a total of 120 participants who were enrolled, 90 subjects were randomly allocated into 2 groups of placebo (n = 45) and quercetin (Sigma Q4951 ≥ 95% purity; Sigma-Aldrich, St. Louis, MO, USA) (n = 45) as shown in Figure 1. The placebo (Avicel PH101; Sigma-Aldrich) produced with the same size, color and smell as quercetin capsules. Random assignment was performed using computer-generated random numbers. Each patient received 250 mg capsules twice daily. Any compliance was checked through weekly telephone interviews and monthly session meetings in the school of public health.
Figure 1

Participants, recruitment, and randomization.

cnr-9-11-g001

Clinical, paraclinical assessments

All participants completed a demographic questionnaire at the beginning and the week 12 of the study. In addition, all other measurements including anthropometric and hematological parameters, were conducted at baseline and week 12. Fasting blood samples were obtained at the baseline and week 12 after a 12-hour overnight fasting. Hematological parameters were measured using Sysmex kx21n. Ferritin was measured by Pishtazteb ELIZA kits (Pishtazteb, Tehran, Iran).

Statistical analysis

All statistical analyses were performed using the SPSS version 20 statistical software (IBM Corp., Armonk, NY, USA). Kolmogorov-Smirnov test was used to assess the normality distribution of variables. Quantitative variables were expressed as a mean ± standard deviation and qualitative variables were expressed in terms of frequency (number and percentage). Paired-samples t-test was used to compare intra-group changes variables and independent t-test was applied to compare the inter-group changes. In all cases, a value for p < 0.05 was considered significant.

RESULTS

Baseline characteristics of the patients

During the intervention, 12 patients (6 people in each group) failed to complete the trial mainly because of immigration and non-adherence (Figure 1). Seventy-eight patients completed the study, 39 individuals in each group. Average age of all patients were of 44.67 ± 10.20 years old. The level of baseline physical activity and demographic data were not significantly different between these two groups (Table 1).
Table 1

Baseline characteristics of patients

cnr-9-11-i001
Characteristics Group p value
Quercetin (n = 39) Placebo (n = 39)
Age (yr) 43.46 ± 11.13 45.89 ± 9.16 0.295*
Sex 0.407
Female 24 (61.54) 26 (66.66)
Male 15 (38.46) 13 (33.33)
Habitat 0.292
Urban 29 (74.36) 32 (82.02)
Rural 10 (25.64) 7 (15.95)
Smoking 6 (15.4) 4 (10.3) 0.368
Physical activity 0.500
Mild 37 (94.9) 36 (92.3)
Moderate 2 (5.1) 3 (7.7)
Data presented as number (%) or mean± standard deviation
Statistical tests were used *independent-sample t-test, χ2 test unless indicated.

Hematological parameters

As shown in Table 2, There was no significant difference in considered parameters between the two groups at baseline. Between-group comparisons also revealed that the level of RBC was significantly higher (p = 0.025), and the level of mean corpuscular volume (MCV; p = 0.004), mean corpuscular hemoglobin (MCH; p = 0.002), and ferritin (p = 0.013) were significantly lower in quercetin group at the end of the trial. However, the values still remained in normal range.
Table 2

Change of hematological parameters from baseline to end of treatment

cnr-9-11-i002
Variables Quercetin (n = 39) Placebo (n = 39) p value*
Female (n = 24) Male (n = 15) Total Female (n = 26) Male (n = 13) Total
WBC (103/ul)
Baseline 6.50 ± 1.90 6.25 ± 0.84 6.40 ± 1.60 7.10 ± 1.62 6.64 ± 1.02 6.93 ± 1.45 0.118
Week 12 6.20 ± 1.84 5.90 ± 1.30 6.10 ± 1.64 6.75 ± 1.60 6.70 ± 1.32 6.74 ± 1.50 0.068
p value 0.266 0.492
Lymphocyte (%)
Baseline 36.15 ± 9.43 38.00 ± 5.10 36.84 ± 8.00 35.00 ± 8.40 37.12 ± 9.30 35.67 ± 8.63 0.534
Week 12 37.65 ± 7.40 35.50 ± 7.02 36.82 ± 7.22 36.10 ± 6.21 35.13 ± 7.22 35.75 ± 6.50 0.495
p value 0.986 0.959
Monocyte (%)
Baseline 8.60 ± 2.90 10.90 ± 2.90 9.50 ± 3.10 7.50 ± 2.62 12.04 ± 4.73 9.00 ± 4.04 0.560
Week-12 8.40 ± 1.90 8.33 ± 2.94 8.35 ± 2.30 9.30 ± 3.62 9.80 ± 4.05 9.50 ± 3.72 0.117
p value 0.082 0.509
Granulocyte (%)
Baseline 55.00 ± 11.25 51.40 ± 6.13 53.61 ± 9.80 56.44 ± 6.70 49.50 ± 9.40 54.12 ± 8.25 0.799
Week 12 54.40 ± 8.73 53.50 ± 10.85 54.01 ± 9.50 54.62 ± 7.92 55.10 ± 8.44 54.80 ± 8.00 0.717
p value 0.810 0.690
HGB (g/dL)
Baseline 13.20 ± 1.00 14.60 ± 1.80 13.72 ± 1.50 13.50 ± 1.02 14.03 ± 1.30 13.70 ± 1.12 0.911
Week 12 13.17 ± 1.00 15.05 ± 0.92 14.00 ± 1.32 13.30 ± 0.61 15.41 ± 3.00 14.00 ± 2.01 0.807
p value 0.465 0.381
RBC (106/ul)
Baseline 4.70 ± 0.43 5.15 ± 0.64 4.90 ± 0.60 4.60 ± 0.40 5.00 ± 0.37 4.72 ± 0.42 0.175
Week 12 5.10 ± 0.60 5.41 ± 0.32 5.22 ± 0.53 4.72 ± 0.30 5.31 ± 0.92 4.92 ± 0.63 0.025
p value 0.002 0.080
HCT (%)
Baseline 40.82 ± 2.63 44.40 ± 4.17 42.20 ± 3.70 40.75 ± 2.50 42.90 ± 2.90 41.50 ± 2.80 0.324
Week 12 40.80 ± 3.70 44.30 ± 2.23 42.12 ± 3.62 40.00 ± 1.20 46.10 ± 7.22 42.02 ± 5.10 0.925
p value 0.890 0.513
MCV (FL)
Baseline 87.30 ± 6.41 87.00 ± 7.04 87.05 ± 6.60 89.00 ± 3.60 86.52 ± 7.30 88.15 ± 5.20 0.416
Week 12 85.00 ± 6.60 85.00 ± 4.40 85.00 ± 5.80 89.40 ± 4.30 87.02 ± 5.64 88.70 ± 4.84 0.004
p value 0.023 0.543
MCH (pg)
Baseline 28.13 ± 2.33 28.40 ± 3.03 28.23 ± 2.60 29.41 ± 1.44 28.30 ± 3.10 29.04 ± 2.16 0.139
Week 12 26.72 ± 3.50 28.22 ± 1.80 27.30 ± 3.01 30.12 ± 2.61 29.00 ± 4.97 29.75 ± 3.54 0.002
p value 0.096 0.162
MCHC (g/dL)
Baseline 32.25 ± 1.44 32.73 ± 1.60 32.44 ± 1.50 33.10 ± 1.22 32.70 ± 1.40 32.95 ± 1.30 0.105
Week 12 32.60 ± 1.50 34.00 ± 1.03 33.13 ± 1.50 33.20 ± 1.02 33.13 ± 1.93 33.18 ± 1.40 0.893
p value 0.029 0.377
RDW-cv (%)
Baseline 13.60 ± 1.10 13.93 ± 1.15 13.70 ± 1.10 13.24 ± 0.80 13.83 ± 1.17 13.44 ± 0.95 0.262
Week 12 13.23 ± 0.93 13.00 ± 0.60 13.13 ± 0.82 13.23 ± 1.33 14.10 ± 1.74 13.51 ± 1.51 0.167
p value 0.005 0.786
PLT (103/ul)
Baseline 257.91 ± 63.63 220.40 ± 53.61 243.50 ± 62.10 263.92 ± 56.44 241.50 ± 48.53 256.44 ± 54.40 0.330
Week 12 249.20 ± 56.33 243.80 ± 46.45 250.10 ± 52.18 284.92 ± 48.90 217.30 ± 58.95 262.40 ± 60.92 0.238
p value 0.679 0.575
MPV (FL)
Baseline 9.45 ± 1.21 8.84 ± 0.80 9.22 ± 1.10 9.20 ± 1.03 9.30 ± 0.93 9.20 ± 1.00 0.957
Week 12 9.95 ± 1.05 9.30 ± 1.30 9.70 ± 1.20 9.40 ± 1.04 9.40 ± 1.03 9.40 ± 1.03 0.205
p value 0.017 0.140
PDW
Baseline 14.82 ± 1.91 15.00 ± 2.10 14.90 ± 1.95 14.80 ± 1.83 14.60 ± 1.95 14.71 ± 1.85 0.692
Week 12 13.84 ± 2.61 13.80 ± 3.50 13.82 ± 2.92 14.13 ± 2.07 14.20 ± 1.90 14.15 ± 2.00 0.574
p value 0.015 0.990
Ferritin (ng/mL)
Baseline 128.85 ± 98.20 148.60 ± 100.17 136.45 ± 98.13 142.87 ± 118.57 129.06 ± 85.00 138.27 ± 108.96 0.938
Week 12 93.50 ± 60.80 84.24 ± 64.45 89.93 ± 61.54 130.66 ± 112.37 162.10 ± 102.82 141.14 ± 107.60 0.013
p value 0.002 0.810
Data presented as mean ± standard deviation. Bold-faced p values indicate statistical significance (p < 0.05).
WBC, white blood cell; HGB, hemoglobin; RBC, red blood cell; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW-cv, red blood cell distribution width-coefficient of variation; PLT, platelet; MPV, mean platelet volume; PDW, platelet distribution width.
Statistical tests were used *independent-sample t-test (total), paired t-test.
End of trial values for RBC (p = 0.002), mean corpuscular hemoglobin concentration (MCHC; p = 0.029), and mean platelet volume (p = 0.017), significantly increased by 0.32 106/ul, 0.69 g/dL, and 0.48 FL, respectively, and the levels of MCV (p = 0.023), RDW-coefficient of variation (p = 0.005), platelet distribution width (p = 0.015), and ferritin (p = 0.002) significantly decreased by 2.05 FL, 0.57%, 1.08 ng/mL, and 46.52 ng/mL, respectively, compare to the baseline in group receiving quercetin. None of the abovementioned variables showed significant changes in placebo group. None of the patients had reported any side-effects, which indicated tolerance to the treatment.

DISCUSSION

Flavonoids and in particular quercetin have controversial effects on hematological parameters. Reviewing the publications over last years, we could not find any related paper, which have been exclusively focused on this topic. In this study, quercetin supplementation significantly increased RBC in intervention group. Flavonoids can increase the production of RBCs by stimulating the secretion of erythropoietin [2021]. Erythrocytes are highly exposed to oxygen and their membrane has high concentration of polyunsaturated fatty acids, which can make them susceptible to oxidative stress [19]. RBCs can also bind polyphenols to their surfaces and play a crucial role in the distribution of polyphenols and protect the erythrocytes membrane against oxidative damage [22]. Quercetin has a great potential in restoring the content of endogenous glutathione in erythrocytes that was depleted by radical generators [18]. In our study, patients had normal ferritin level at baseline. Ferritin level had been significantly decreased in the quercetin group from the baseline to the end of treatment. In enterocytes, quercetin acts as an electron donor and facilitates inorganic iron absorption. However, quercetin can also repress the expression of ferroportin and hephaestin, and subsequently inhibits basolateral iron absorption [2324]. Another possible mechanism is that quercetin may be able to chelate iron in the enterocytes and the quercetin iron complex being retained in the cytosol [25]. Therefore, the reduction in ferritin level may be as the result of functional cellular iron deficiency [26]. Inconsistent with other findings of our study, including increased levels of RBC and hemoglobin, the levels of MCV and MCH significantly decreased in quercetin group. It is possibly due to erythrocytosis which occur in 3% of patients at the early stage of anemia [27].
Supporting our findings in a study conducted by Keskin et al. [20], supplementation with quercetin in streptozotocin induced diabetic rats has not shown any significant changes on MCV, MCH, and MCHC, but RBC count significantly increased in group receiving quercetin. Similarly in another animal study, rabbits receiving 3 different doses of guercetin for 90 days 3 times a week, exhibited slight changes in some hematological parameters including: RBC, hemoglobin, and hematocrit; however, the differences were not significant between these two groups [28]. In contrast with our results, Kasmi et al. [17] demonstrated that co-administration of quercetin (20 mg/kg) improved the levels of platelet and white blood cells in rats received different doses of difenoconazole to liver injury induction [17]. In similar manner, quercetin supplementation (50 mg/kg) had a significant favorable effect on polychlorinated biphenyls induced hematological changes in adult male Wistar rats [29]. Mahmoud et al. [21] indicated that MCV, MCH, and MCHC increased to near normal amounts in diabetic rats receiving citrus flavonoids.

CONCLUSION

The effect of flavonoids on hematological profile can be simulated to a 2-edged sword. As we described mechanisms previously, flavonoids might either cause or cure anemia. In this work, RBC increased and ferritin decreased significantly in group receiving quercetin compared to those in placebo group but the values of RBC and ferritin still remained in normal range throughout the study period. It is worth mentioning that none of the patients had reported any side-effects and this indicate that the quercetin treatment was well-tolerated by the patients.

Notes

Conflict of Interest The authors declare that they have no competing interests.

References

1. Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014; 20:15539–15548.
crossref pmid pmc
2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55:2005–2023.
crossref pmid
3. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016; 65:1038–1048.
crossref pmid
4. Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J Gastroenterol. 2018; 24:3361–3373.
crossref pmid pmc
5. Moghaddasifar I, Lankarani KB, Moosazadeh M, Afshari M, Ghaemi A, Aliramezany M, Afsar Gharebagh R, Malary M. Prevalence of non-alcoholic fatty liver disease and its related factors in Iran. Int J Organ Transplant Med. 2016; 7:149–160.
pmid pmc
6. Shrestha UK. Non-alcoholic fatty liver disease (NAFLD) is it an emerging risk factor for coronary artery disease? J Adv Intern Med. 2012; 1:1–2.
crossref
7. Ajmal MR, Yaccha M, Malik MA, Rabbani MU, Ahmad I, Isalm N, Abdali N. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α. Indian Heart J. 2014; 66:574–579.
crossref pmid pmc
8. Terao J. Factors modulating bioavailability of quercetin-related flavonoids and the consequences of their vascular function. Biochem Pharmacol. 2017; 139:15–23.
crossref pmid
9. Lesjak M, Beara I, Simin N, Pintać D, Majkić T, Bekvalac K, Orčić D, Mimica-Dukić N. Antioxidant and anti-inflammatory activities of quercetin and its derivatives. J Funct Foods. 2018; 40:68–75.
crossref
10. Petersen B, Egert S, Bosy-Westphal A, Müller MJ, Wolffram S, Hubbermann EM, Rimbach G, Schwarz K. Bioavailability of quercetin in humans and the influence of food matrix comparing quercetin capsules and different apple sources. Food Res Int. 2016; 88:159–165.
crossref
11. Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res. 2013; 47:869–880.
crossref pmid
12. Arias CF, Arias CF. How do red blood cells know when to die? R Soc Open Sci. 2017; 4:160850.
crossref
13. Diederich L, Suvorava T, Sansone R, Keller TC 4th, Barbarino F, Sutton TR, Kramer CM, Lückstädt W, Isakson BE, Gohlke H, Feelisch M, Kelm M, Cortese-Krott MM. On the effects of reactive oxygen species and nitric oxide on red blood cell deformability. Front Physiol. 2018; 9:332.
crossref pmid pmc
14. Mohanty JG, Nagababu E, Rifkind JM. Red blood cell oxidative stress impairs oxygen delivery and induces red blood cell aging. Front Physiol. 2014; 5:84.
crossref pmid pmc
15. Yang W, Huang H, Wang Y, Yu X, Yang Z. High red blood cell distribution width is closely associated with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2014; 26:174–178.
crossref pmid
16. Stein J, Connor S, Virgin G, Ong DE, Pereyra L. Anemia and iron deficiency in gastrointestinal and liver conditions. World J Gastroenterol. 2016; 22:7908–7925.
crossref pmid pmc
17. Kasmi S, Bkhairia I, Harrabi B, Mnif H, Marrakchi R, Ghozzi H, Kallel C, Nasri M, Zeghal K, Jamoussi K, Hakim A. Modulatory effects of quercetin on liver histopathological, biochemical, hematological, oxidative stress and DNA alterations in rats exposed to graded doses of score 250. Toxicol Mech Methods. 2018; 28:12–22.
crossref pmid
18. Mikstacka R, Rimando AM, Ignatowicz E. Antioxidant effect of trans-resveratrol, pterostilbene, quercetin and their combinations in human erythrocytes in vitro. Plant Foods Hum Nutr. 2010; 65:57–63.
crossref pmid
19. Al-Omair MA, Sedky A, Ali A, Elsawy H. Ameliorative potentials of quercetin against lead-induced hematological and testicular alterations in Albino rats. Chin J Physiol. 2017; 60:54–61.
crossref pmid
20. Keskin E, Dönmez N, Kılıçarslan G, Kandır S. Beneficial effect of quercetin on some haematological parameters in streptozotocin-induced diabetic rats. Bull Environ Pharmacol Life Sci. 2016; 5:65–68.
21. Mahmoud AM. Hematological alterations in diabetic rats - Role of adipocytokines and effect of citrus flavonoids. EXCLI J. 2013; 12:647–657.
pmid pmc
22. Koren E, Kohen R, Ginsburg I. Polyphenols enhance total oxidant-scavenging capacities of human blood by binding to red blood cells. Exp Biol Med (Maywood). 2010; 235:689–699.
crossref pmid
23. Xiao L, Luo G, Tang Y, Yao P. Quercetin and iron metabolism: what we know and what we need to know. Food Chem Toxicol. 2018; 114:190–203.
crossref pmid
24. Lesjak M, Balesaria S, Skinner V, Debnam ES, Srai SK. Quercetin inhibits intestinal non-haem iron absorption by regulating iron metabolism genes in the tissues. Eur J Nutr. 2019; 58:743–753.
crossref pmid
25. Mazhar M, Faizi S, Gul A, Kabir N, Simjee SU. Effects of naturally occurring flavonoids on ferroportin expression in the spleen in iron deficiency anemia in vivo. RSC Adv. 2017; 7:23238–23245.
crossref
26. Lesjak M, Hoque R, Balesaria S, Skinner V, Debnam ES, Srai SK, Sharp PA. Quercetin inhibits intestinal iron absorption and ferroportin transporter expression in vivo and in vitro. PLoS One. 2014; 9:e102900.
crossref
27. Hoffman R, Benz EJ Jr, Silberstein LE, Heslop H, Anastasi J, Weitz J. Hematology: basic principles and practice. 6th ed. Philadelphia (PA): Elsevier Health Sciences;2013.
28. Petruška P, Kalafová A, Kolesárová A, Zbynovská K, Latacz A, Capcarová M. Effect of quercetin on haematological parameters of rabbits: agender comparison. J Microbiol Biotechnol Food Sci. 2013; 2:1540–1549.
29. Selvakumar K, Bavithra S, Suganya S, Ahmad Bhat F, Krishnamoorthy G, Arunakaran J. Effect of quercetin on haematobiochemical and histological changes in the liver of polychlorined biphenyls-induced adult male Wistar rats. J Biomark. 2013; 2013:960125.
crossref
TOOLS
ORCID iDs

Yahya Pasdar
https://orcid.org/0000-0003-0434-6992

Farhad Oubari
https://orcid.org/0000-0003-0281-0544

Mahin Nikougoftar Zarif
https://orcid.org/0000-0002-6727-9785

Mehrnaz Abbasi
https://orcid.org/0000-0003-4287-2133

Azizollah Pourmahmoudi
https://orcid.org/0000-0001-6931-169X

Mahboobe Hosseinikia
https://orcid.org/0000-0002-8590-0264

Similar articles